Expert Commentary
View AllPublications
Chronic opioid therapy and preventive services in rural primary care: an Oregon rural practice-based research network study.
A different kind of co-morbidity: Understanding posttraumatic stress disorder and chronic pain
The impact of enrollment in a specialized interdisciplinary neuropathic pain clinic
Association between urine drug test results and treatment outcome in high-risk chronic pain patients on opioids
The role of core strengthening for chronic low back pain.
Buckley DI, Calvert JF, Lapidus JA, et al.
Ann Fam Med. 2010;8(3):237-44.
PURPOSE:...
Ann Fam Med. 2010;8(3):237-44.
PURPOSE:...
A different kind of co-morbidity: Understanding posttraumatic stress disorder and chronic pain
Beck JG, Clapp JD.
Psychol Trauma. 2011 Jun;3(2):101-108.
Many traumatic events leave...
Psychol Trauma. 2011 Jun;3(2):101-108.
Many traumatic events leave...
The impact of enrollment in a specialized interdisciplinary neuropathic pain clinic
Garven A, Brady S, Wood S, Hatfield M, Bestard J, Korngut L, Toth C.
Pain Res Manag. 2011...
Pain Res Manag. 2011...
Association between urine drug test results and treatment outcome in high-risk chronic pain patients on opioids
Barth KS, Becker WC, Wiedemer NL, Mavandadi S, Oslin DW, Meghani SH, Gallagher RM.
J Addict...
J Addict...
The role of core strengthening for chronic low back pain.
Akuthota V, Standaert CJ, Chimes GP.
PM R. 2011 Jul;3(7):664-70.
PM R. 2011 Jul;3(7):664-70.







Pain Genomics
Debra A. Schwinn, MD, Alex Cahana, MD, PhD
Debra A. Schwinn, MD
Professor and Chair—Department of Anesthesiology
University of Washington Medical Center
Seattle, WA
Alex Cahana, MD, PhD
Professor—Anesthesiology and Pain Medicine
Adjunct Professor—Bioethics and Humanities, Radiology
Chief—Division of Pain Medicine
Department of Anesthesiology and Pain Medicine
University of Washington Medical Center for Pain Relief
Seattle, WA
Patients may have genetic alleles that affect pain sensitivity or increase the risk for chronic pain development. Alternatively, polymorphisms in genes encoding signaling receptors, metabolic enzymes, and enzymes that mediate medication bioavailability will affect patient responses to medical management. For instance, single-nucleotide polymorphisms in the gene encoding the mu-opioid receptor contribute to variability in patient responses to opioids. Already, genomic analyses have facilitated methods to predict patient pain after surgery, diagnose chronic pain syndromes, monitor interventional drug therapy, and evaluate response to other interventions. At the 2010 Annual Meeting of the American Academy of Pain Medicine, Dr. Schwinn delivered a plenary talk on various areas of genomics and their significant implications for the current and future practice of clinical pain medicine.
References